- Home
- NARI vs GERN Comparison
NARI vs GERN Comparison
Compare NARI & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NARI
- GERN
- Stock Information
- Founded
- NARI 2011
- GERN 1990
- Country
- NARI United States
- GERN United States
- Employees
- NARI N/A
- GERN N/A
- Industry
- NARI Medical/Dental Instruments
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- NARI Health Care
- GERN Health Care
- Exchange
- NARI Nasdaq
- GERN Nasdaq
- Market Cap
- NARI 3.0B
- GERN 2.5B
- IPO Year
- NARI 2020
- GERN 1996
- Fundamental
- Price
- NARI $49.66
- GERN $4.07
- Analyst Decision
- NARI Buy
- GERN Strong Buy
- Analyst Count
- NARI 10
- GERN 10
- Target Price
- NARI $59.13
- GERN $6.95
- AVG Volume (30 Days)
- NARI 918.3K
- GERN 10.2M
- Earning Date
- NARI 10-28-2024
- GERN 11-07-2024
- Dividend Yield
- NARI N/A
- GERN N/A
- EPS Growth
- NARI N/A
- GERN N/A
- EPS
- NARI N/A
- GERN N/A
- Revenue
- NARI $574,498,000.00
- GERN $29,480,000.00
- Revenue This Year
- NARI $24.59
- GERN $30,930.80
- Revenue Next Year
- NARI $18.28
- GERN $315.72
- P/E Ratio
- NARI N/A
- GERN N/A
- Revenue Growth
- NARI 22.41
- GERN 9199.68
- 52 Week Low
- NARI $36.73
- GERN $1.64
- 52 Week High
- NARI $67.13
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- NARI 53.46
- GERN 50.64
- Support Level
- NARI $47.96
- GERN $3.60
- Resistance Level
- NARI $52.59
- GERN $3.86
- Average True Range (ATR)
- NARI 2.13
- GERN 0.21
- MACD
- NARI -0.36
- GERN 0.01
- Stochastic Oscillator
- NARI 29.77
- GERN 52.22
About NARI Inari Medical Inc.
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.